C
VIR icon

Covestor’s Vir Biotechnology VIR Stock Holding History

Covestor’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
39
+28
+255% +$266 ﹤0.01% 2874
2026
Q1 		$0 Hold
11
– – ﹤0.01% 2812
2025
Q4 		$0 Hold
11
– – ﹤0.01% 2777
2025
Q3 		$0 Hold
11
– – ﹤0.01% 2818
2025
Q2 		$0 Sell
11
-1
-8% -$5 ﹤0.01% 2798
2025
Q1 		$0 Sell
12
-15
-56% -$133 ﹤0.01% 2768
2024
Q4 		$0 Buy
27
+16
+145% +$126 ﹤0.01% 2784
2024
Q3 		$0 Sell
11
-1
-8% -$9 ﹤0.01% 2815
2024
Q2 		$0 Hold
12
– – ﹤0.01% 2801
2024
Q1 		$0 Sell
12
-1
-8% -$10 ﹤0.01% 2788
2023
Q4 		$0 Sell
13
-4,524
-100% -$41.3K ﹤0.01% 2764
2023
Q3 		$43K Sell
4,537
-4,668
-51% -$66.6K 0.03% 834
2023
Q2 		$226K Buy
9,205
+9,196
+102,178% +$231K 0.17% 86
2023
Q1 		$0 Hold
9
– – ﹤0.01% 2631
2022
Q4 		$0 Hold
9
– – ﹤0.01% 2650
2022
Q3 		$0 Sell
9
-190
-95% -$4.83K ﹤0.01% 2662
2022
Q2 		$5K Sell
199
-83
-29% -$1.94K ﹤0.01% 1434
2022
Q1 		$7K Buy
282
+125
+80% +$3.71K ﹤0.01% 1430
2021
Q4 		$7K Buy
+157
New +$6.15K 0.01% 1182

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Covestor's VIR Position: Q2 2026 in Review

Covestor increased its Vir Biotechnology (VIR) stake by 255% in Q2 2026, buying an estimated $266 and bringing the position to 39 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

Covestor first reported a position in VIR in Q4 2021 and has held it in 19 quarters since. The position peaked at $226K in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Covestor held 39 shares of Vir Biotechnology worth $0 as of Q2 2026.
  • Covestor bought 28 Vir Biotechnology shares in Q2 2026, an estimated $266.
  • Vir Biotechnology made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2874 holding.
  • Covestor first reported a position in Vir Biotechnology in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Vir Biotechnology position peaked at $226K in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.